(12) **Translation of European patent specification**

(11) **NO/EP 3456330 B1**

(19) NO

NORWAY

(51) Int Cl.

A61K 31/573 (2006.01) ***A61P 35/04 (2006.01)***
A61P 5/46 (2006.01) ***A61P 43/00 (2006.01)***
A61P 35/00 (2006.01) ***C07J 5/00 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2021.10.04
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.05.19
(86)	European Application Nr.	18198653.0
(86)	European Filing Date	2015.10.07
(87)	The European Application's Publication Date	2019.03.20
(30)	Priority	2014.10.08, EP, 14188063
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(62)	Divided application	EP3204400, 2015.10.07
(73)	Proprietor	Cosmo Technologies Ltd, Riverside II Sir John Rogerson's Quay, Dublin 2, Irland
(72)	Inventor	Gerloni, Mara, 2933 Ariane Drive, San Diego, CA 92117, USA
(74)	Agent or Attorney	Budde Schou A/S, Dronningens Tværgade 30, 1302 KØBENHAVN K, Danmark

(54) Title **CORTEXOLONE 17ALPHA-VALERATE FOR USE IN THE TREATMENT OF TUMOURS**

(56) References Cited:

WO-A2-2009/019138, US-A- 3 152 154,
SEAN EKINS ET AL: "Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR", PLOS COMPUTATIONAL BIOLOGY, vol. 5, no. 12, 11 December 2009 (2009-12-11), pages e1000594-1, XP055549623, DOI: 10.1371/journal.pcbi.1000594 -& Sean Ekins ET AL: "Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR", PLoS Computational Biology, 11 December 2009 (2009-12-11), page e1000594, XP055549646, DOI: 10.1371/journal.pcbi.1000594 Retrieved from the Internet: URL:https://journals.plos.org/ploscompbiol /article/file?id=10.1371/journal.pcbi.1000594.s002&type=supplementary [retrieved on 2019-01-30] -& Sean Ekins ET AL: "Challenges Predicting Ligand-Receptor Interactions of Promiscuous Proteins: The Nuclear Receptor PXR", PLoS Computational Biology, 11 December 2009 (2009-12-11), page e1000594, XP055549647, DOI: 10.137
PATRIZIA FERRABOSCHI ET AL: "A full conformational characterization of antiandrogen cortexolone-17[alpha]-propionate and related compounds through theoretical calculations and nuclear magnetic resonance spectroscopy", MEDCHEMCOMM, vol. 5, no. 7, 1 January 2014 (2014-01-01) , pages 904-914, XP55224342, United Kingdom ISSN: 2040-2503, DOI: 10.1039/C4MD00049H

DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1998, BONSMANN U ET AL: "Metabolisation and receptor affinity of topically applied esters of glucocorticoids", XP002788474, Database accession no. EMB-1998329776 & BONSMANN U ET AL: "Metabolisation and receptor affinity of topically applied esters of glucocorticoids", H+G ZEITSCHRIFT FUR HAUTKRANKHEITEN 1998 DE, vol. 73, no. 9, 1998, pages 581-590, ISSN: 0301-0481
DATABASE HCAPLUS, [Online] 1 January 1979 (1979-01-01), CUTLER GORDON B ET AL: "11-Deoxycortisol: a glucocorticoid antagonist in vivo", XP002749428, retrieved from HCAPLUS; STN Database accession no. 1979-469056 & CUTLER G B JR ET AL: "11-Deoxycortisol: a glucocorticoid antagonist in vivo.", ENDOCRINOLOGY JUN 1979, vol. 104, no. 6, June 1979 (1979-06), pages 1839-1844, ISSN: 0013-7227
GIUSEPPE CELASCOA ET AL: "Pharmacological Profile of 9,11-Dehydrocortexolone 17[alpha]-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, ECV EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 55, no. 10, 1 January 2005 (2005-01-01), pages 581-587, XP008175216, ISSN: 0004-4172, DOI: 10.1055/S-0031-1296908
FERRABOSCHI P ET AL: "Lipase-catalyzed preparation of corticosteroid 17@a-esters endowed with antiandrogenic activity", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 49, no. 31, 28 July 2008 (2008-07-28) , pages 4610-4612, XP022757401, ISSN: 0040-4039, DOI: 10.1016/J.TETLET.2008.05.086 [retrieved on 2008-05-23]

Patentkrav

1. Forbindelse av formel:



korteksolon-17α-valerat

for anvendelse ved behandling av prostatakarsinom; brystkarsinom; pankreatisk karsinom; lungekarsinom; gastrointestinalkanalkarsinom, nyrekreft; skjoldbruskkarsinom; livmorkarsinom eller binyrekarsinom; og hvori prostatakarsinomet er resistent mot anti-androgen målrettet terapi.

2. Forbindelsen for anvendelse ifølge krav 1, hvori den anti-androgen målrettede behandlingen er enzalutamid.

3. Farmasøytisk sammensetning omfattende en forbindelse av formel:



korteksolon-17α-valerat

for anvendelse ved behandling av prostatakarsinom; brystkarsinom; pankreatisk karsinom; lungekarsinom; gastrointestinalkanalkarsinom, nyrekreft; skjoldbruskkjertelkarsinom; livmorkarsinom eller binyrekarsinom; og hvori prostatakarsinomet er resistent mot anti-androgen målrettet terapi.

4. Den farmasøytiske sammensetningen for anvendelse ifølge krav 3, hvori den anti-androgenmålrettede behandlingen er enzalutamid.

5. Den farmasøytiske sammensetningen for anvendelse ifølge krav 3 eller 4 og minst én annen aktiv ingrediens, fortrinnsvis en kjemoterapeutisk aktiv ingrediens.

6. Den farmasøytiske sammensetningen for anvendelse ifølge et hvilket som helst av kravene 3−5, for anvendelse med en andre sammensetning omfattende minst én annen aktiv ingrediens, fortrinnsvis en kjemoterapeutisk aktiv ingrediens, for samtidig, separat eller sekvensiell administrering.